Ben Richardson, CEO at SulNOx, confident they can cost-effectively decarbonise commercial shipping. Watch the video here.
Director of ONS has just said this on sky news
"antibody test being developed by University of Oxford has been proven to work and is being scaled up"
Must be odx no?
Bit of research on Data Monitoring Committees:
According to the Food and Drug Administration (FDA) Guidance for Clinical Trial Sponsors – Establishment and Operation of Clinical Trial Data Monitoring Committees (DMC)[1], ‘A clinical trial DMC is a group of individuals with pertinent expertise that reviews on a regular basis accumulating data from one or more ongoing clinical trials’. The FDA guidance further explains that ‘The DMC advises the sponsor regarding the continuing safety of trial subjects and those yet to be recruited to the trial, as well as the continuing validity and scientific merit of the trial’.
I'm sure the sponsor can access data as the trial is ongoing, it is those that are directly involved with the trial (doctors and patients) that cannot. Read this on the Nottingham University hospital covid files too...
https://clinicaltrials.gov/ct2/keydates/NCT04385095
Looks like Synairgen submitted on 24th April so this can only be good news as we've crossed the pond. Not sure of the significance yet...
Biosure seem pretty confident they've got a test to roll out, but they are anticipating manufacturing 1 million per month. How many do we think are going to be required per month going forward?
Can you check for antibodies with saliva? You sure it's not an antigen test?
Totally agree with the dentistry angle, I'm a dentist and I'm worried about going back, there's well over 100 million dental appointments per year. I'd want to test every patient I treat. When we do go back to work, we will be treating 5-6 patients a day rather than 30-40, so for private dentists you're talking a huge pay cut (get your violins out) unless we can test everyone that comes through the door.
https://www.nuh.nhs.uk/guidance-researchers?smbfolder=689
Some people were asking about whether they can partially unblind the trial analyse any interim results. I've located the covid-19 template library for Nottingham University hospital who are part of sng001. If you read the 'managing and code breaks and unblinding' it does say, near the end of the document, that they can unblind for interim analysis (for the sponsor and R&I) as long as the research team and patients are not told.
I don't know whether that has happenend with this trial but it looks like it is possible should they wish.
No it's not ideal because they know how their drug works and they wouldn't be allowed to just go straight to non-hospitalised patients. This was always planned if you look at the sg016 eu clinical register trial document.
It appeared on the graphs from the daily update that the death rate (not number of deaths) is higher outside hospital than inside hospital...the results can't come soon enough for these poor people...
FWIW my reading of it all is that they are having good results with sng001 and that's why they have suddenly brought in other drugs that increase the levels of interferons in the body. This new drug for the ACCORD trial seems to have come out of nowhere....of course this could be a bad case of confirmation bias :)
So this is a new study on the hra website, it says 'new' rather than amended at the top and was updated today? A new study now being able to treat non hospitalised patients sooner with pic test. This has to be what Han**** was on about??